Retrospective Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Psychiatry. May 19, 2024; 14(5): 644-652
Published online May 19, 2024. doi: 10.5498/wjp.v14.i5.644
Therapeutic effect and psychological impact of aspirin plus edaravone on patients with cerebral infarction
Tian-Shu Wang, Li-Jun Jing
Tian-Shu Wang, Li-Jun Jing, Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China
Author contributions: Wang TS designed the study and wrote the manuscript; Wang TS and Jing LJ performed the data collection, conducted the data analysis and revised the manuscript. All authors approved the final version of the manuscript.
Institutional review board statement: The study was approved by the Institutional review board of First Hospital Affiliated of Zhengzhou University.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tian-Shu Wang, PhD, Doctor, Department of Neurology, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou 450052, Henan Province, China. fccwangts@zzu.edu.cn
Received: January 12, 2024
Revised: March 26, 2024
Accepted: April 15, 2024
Published online: May 19, 2024
Processing time: 125 Days and 4.3 Hours
Abstract
BACKGROUND

Cerebral infarction (CI) is characterized by a high prevalence, disability, and mortality. Timely or improper treatment greatly affects patient prognosis.

AIM

To explore the drug efficacy of aspirin plus edaravone and to explore their effect on quality of life (QOL), anxiety and depression in CI patients.

METHODS

We retrospectively analyzed the records of 124 CI patients treated between June 2019 and February 2021 who were assigned to an observation group (OG) (combination therapy of aspirin and edaravone, 65 patients) or a control group (CG) (aspirin monotherapy, 59 patients). The therapeutic effects, pre- and posttreatment National Institutes of Health Stroke Scale (NIHSS) scores, activities of daily living, degree of cognitive impairment, protein levels of glial fibrillary acidic protein (GFAP), neuron-specific enolase (NSE) and S-100B, occurrence of adverse reactions, and serum high-sensitivity C-reactive protein (hs-CRP), interleukin (IL)-6 and tumor necrosis factor (TNF)-α were evaluated, detected and compared between the two groups. Finally, posttreatment QOL, anxiety, and depression were assessed by the Medical Outcomes Study 36- Item Short Form Health Survey Scale, Self-rating Depression Scale (SDS), and Self-rating Anxiety Scale (SAS), respectively.

RESULTS

Compared with the CG, the OG had markedly better therapeutic effects, greater improvements in activities of daily living, and better alleviation in cognitive dysfunction after treatment, as well as lower posttreatment NIHSS scores and serum NSE, GFAP, S-100B, hs-CRP, IL-6, and TNF-α levels; the OG was similar to the CG in terms of adverse reactions but was better than the CG in terms of posttreatment QOL; and the OG also had lower SDS and SAS scores than the CG after treatment.

CONCLUSION

Aspirin plus edaravone had a good curative effect on CI. It can reverse cranial nerve damage in patients, improve neurological function and prognosis, and alleviate inflammation, anxiety, and depression; thus, it is considered safe and worthy of clinical application.

Keywords: Aspirin; Edaravone; Cerebral infarction; Efficacy; Quality of life

Core Tip: Edaravone, a commonly used free radical scavenger in clinical practice, can reduce the concentration of hydroxyl radicals and inhibit lipid peroxidation activity, ultimately achieving effects such as reducing endothelial cell damage and delaying neuronal cell death. It is currently the main drug used for the treatment of acute cerebral infarction. In addition, it can theoretically play a synergistic role with aspirin to improve therapeutic effectiveness, but there are few relevant studies to confirm our view. This study confirmed that aspirin combined with edaravone has more prominent efficacy and other clinical advantages in the treatment of cerebral infarction patients.